H. Lundbeck A/S

Copenhagen Stock Exchange:HLUN-B.CO

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Denmark

Market Cap

USD 5.35 B

Share Price

USD 5.60

Avg Daily Volume

582,647

Change (1 day)

0.14%

Change (1 year)

2.60%

Change (YTD)

-2.56%

H. Lundbeck A/S Accounts Payable for the year ending December 31, 2024: USD 604.81 M

H. Lundbeck A/S Accounts Payable is USD 604.81 M for the year ending December 31, 2024, a -7.35% change year over year. Accounts payable are amounts owed by the company to suppliers or vendors for goods or services received but not yet paid.

H. Lundbeck A/S Accounts Payable for the year ending December 31, 2023 was USD 652.77 M, a 7.01% change year over year.
H. Lundbeck A/S Accounts Payable for the year ending December 31, 2022 was USD 610.02 M, a 1.97% change year over year.
H. Lundbeck A/S Accounts Payable for the year ending December 31, 2021 was USD 598.22 M, a -2.35% change year over year.
H. Lundbeck A/S Accounts Payable for the year ending December 31, 2020 was USD 612.61 M, a 4.05% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Accounts Payable	Short-Term Debt	Long-Term Debt	Total Liabilities

Copenhagen Stock Exchange: HLUN-B.CO

H. Lundbeck A/S

CEO	Mr. Charl van Zyl
IPO Date	June 10, 2022
Location	Denmark
Headquarters	Ottiliavej 9
Employees	5,707
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.